Who are Warfarin-Natrium's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Coumadin, Marevan®, Standard dose oral anticoagulant, Nadroparin Calcium and Warfarin, Sodium warfarin, Warfarin (Coumadin).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/warfarin-natrium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Warfarin-Natrium — Competitive Intelligence Brief

Warfarin-Natrium (Warfarin-Natrium) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin K antagonist. Area: Cardiovascular.

phase 3 Vitamin K antagonist Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Warfarin-Natrium (Warfarin-Natrium) — University Hospital, Bonn. Warfarin-Natrium is an anticoagulant that inhibits vitamin K-dependent clotting factors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Warfarin-Natrium TARGET	Warfarin-Natrium	University Hospital, Bonn	phase 3	Vitamin K antagonist
Coumadin	warfarin	Generic (originally Wisconsin Alumni Research Foundation)	marketed	Vitamin K antagonist (anticoagulant)	Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7	1954-01-01
Marevan®	Marevan®	Federal University of São Paulo	marketed	Vitamin K antagonist (coumarin anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)
Standard dose oral anticoagulant	Standard dose oral anticoagulant	Korea University Guro Hospital	marketed	Vitamin K antagonist (warfarin-type oral anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)
Nadroparin Calcium and Warfarin	Nadroparin Calcium and Warfarin	Shanghai Zhongshan Hospital	marketed	Anticoagulant combination (low-molecular-weight heparin + vitamin K antagonist)	Antithrombin III (nadroparin); Vitamin K-dependent clotting factors II, VII, IX, X (warfarin)
Sodium warfarin	Sodium warfarin	University of Padova	marketed	Vitamin K antagonist (coumarin anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)
Warfarin (Coumadin)	Warfarin (Coumadin)	University of Michigan	marketed	Vitamin K antagonist (oral anticoagulant)	Vitamin K epoxide reductase (VKORC1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin K antagonist class)

Joon Bum Kim · 1 drug in this class
Population Health Research Institute · 1 drug in this class
US Department of Veterans Affairs · 1 drug in this class
University Hospital, Bonn · 1 drug in this class
University Hospital, Limoges · 1 drug in this class
Yunhe Pharmaceutical (Tianjin) Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Warfarin-Natrium — Competitive Intelligence Brief. https://druglandscape.com/ci/warfarin-natrium. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab